Skip to main content
Premium Trial:

Request an Annual Quote

Response Genetics Cites Delay in Test Samples for Q4 Revenue Decline

NEW YORK (GenomeWeb News) – Response Genetics reported after the close of the market on Thursday that its fourth-quarter revenues fell 41 percent due primarily to a delay in receiving clinical samples from pharmaceutical customers.

The Los Angeles-based molecular diagnostics test developer and lab operator reported revenues of $1.4 million for the three-month period ended Dec. 31, compared to revenues of $2.4 million for the fourth quarter of 2007. The company said that it anticipates receiving those delayed clinical samples in 2009 through 2010.

Response Genetics posted a net loss of $3.4 million, or $.33 per share, versus a loss of $911,555, or $.09 per share, for the fourth quarter of 2007.

The company's R&D expenses dropped to $436,736 from $566,293, while its general and administrative spending climbed to $2.3 million from $1.3 million year over year.

Response Genetics also recognized an impairment charge of $893,826 related to its UK facility, which it closed in order to consolidate operations at its CLIA-certified lab in Los Angeles.

For full-year 2008, Response Genetics brought in revenues of $7.1 million, down 9 percent from revenues of $7.8 million for 2007. Its net loss for the year rose 86 percent to $9.5 million, or $.93 per share, from $5.1 million, or $.78 per share.

The firm's R&D expenses for 2008 fell to $2.2 million from $2.5 million, and its general and administrative spending jumped to $7.9 million from $5.2 million.

"Sales of our ResponseDX diagnostic tests are off to a promising start in 2009 with approximately 500 tests processed in the first quarter compared to approximately 300 tests processed in the fourth quarter of 2008 — a 60 percent increase in tests processed," Kathleen Danenberg, president and CEO of Response Genetics, said in a statement.

Response Genetics finished the year with $9.5 million in cash and cash equivalents.

The Scan

Pig Organ Transplants Considered

The Wall Street Journal reports that the US Food and Drug Administration may soon allow clinical trials that involve transplanting pig organs into humans.

'Poo-Bank' Proposal

Harvard Medical School researchers suggest people should bank stool samples when they are young to transplant when they later develop age-related diseases.

Spurred to Develop Again

New Scientist reports that researchers may have uncovered why about 60 percent of in vitro fertilization embryos stop developing.

Science Papers Examine Breast Milk Cell Populations, Cerebral Cortex Cellular Diversity, Micronesia Population History

In Science this week: unique cell populations found within breast milk, 100 transcriptionally distinct cell populations uncovered in the cerebral cortex, and more.